RBC Capital analyst Brian Abrahams lowered the firm’s price target on Karyopharm (KPTI) to $19 from $30 and keeps an Outperform rating on the shares. The company reported a solid quarter for Xpovio sales, while the reduction of financing overhangs, and MF timelines intact for March 2026 make for a favorable risk/reward setup, the analyst tells investors in a research note. RBC adds however that its reduced price target reflects the recent financing transactions.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm Therapeutics Reports Q3 2025 Financial Results
- Karyopharm files to sell 9.57M shares of common stock for holders
- Karyopharm files to sell 2.81M shares of common stock for holders
- Karyopharm reports Q3 EPS ($3.82), consensus ($3.25)
- Karyopharm sees FY25 revenue $140M-$155M, consensus $150.22M